Blockchain Registration Transaction Record

GeoVax Highlights CDC Report on Sustained Clade Ib Mpox Transmission in U.S.

GeoVax highlights CDC's report of sustained Clade Ib mpox transmission in the U.S. and advances GEO-MVA vaccine to Phase 3, emphasizing preparedness and vaccine supply.

The CDC's confirmation of likely sustained Clade Ib mpox transmission in the United States marks a pivotal shift in the virus's epidemiology, moving beyond travel-associated cases to domestic spread. This development matters because it signals that mpox is becoming an endemic threat, requiring robust public health infrastructure and vaccine readiness. GeoVax's accelerated development of GEO-MVA, with a pivotal Phase 3 trial set to begin in late 2026, could provide a critical additional vaccine option, enhancing supply resilience and biosecurity. As infectious diseases continue to cross borders, proactive measures—such as diversified vaccine supply and scalable manufacturing—are essential to protect at-risk populations and prevent future crises. This news underscores the need for sustained investment in preparedness, not just reaction, to safeguard global health.